English

ALPINE IMMUNE SCIENCES, INC.

EDGAR

ALPN Quarterly report (10-Q) · filed 2024-05-09

78 filing records in this dataset, filed from 2015-05-13 to 2024-05-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

7.03 million USD

2024 Q1 · USD

Exact inputs and evidence

Revenue: 7032000 USD Source

Operating margin

-322.75%

2024 Q1 · %

Exact inputs and evidence

Operating Income: -22696000 USD Source
Revenue: 7032000 USD Source

Operating cash flow

-27.7 million USD

2024 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -27690000 USD Source

Free cash flow

-27.7 million USD

2024 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -27690000 USD Source
Capital Expenditure: 19000 USD Source

Cash and cash equivalents: 33 million USD 2024-03-31 Source
Exact value

33015000 USD
Long-term debt including current maturities: 1.6 million USD 2023-03-31 Source
Exact value

1600000 USD
Shares outstanding: 65.6 million shares 2024-03-31 Source
Exact value

65552322 shares

Reported share-count change

37.26% · 17.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

47758007 shares · 2023-03-31· Source
65552322 shares · 2024-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-05-09.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2023-12-31
Operating income: 10 of 11 periods available· newest 2023-12-31
Net income: 10 of 11 periods available· newest 2023-12-31
Operating cash flow: 10 of 11 periods available· newest 2023-12-31
Capital expenditure: 10 of 11 periods available· newest 2023-12-31
Total assets: 9 of 11 periods available· newest 2023-12-31
Total liabilities: 8 of 11 periods available· newest 2023-12-31
Current assets: 9 of 11 periods available· newest 2023-12-31
Current liabilities: 9 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2022-12-31
Shares outstanding: 9 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+95.8%

Prior period

USD 30.06 million

2022-01-01 – 2022-12-31
Current period

USD 58.88 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

58876000 − 30064000 = 28812000 USD

30064000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
58876000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Year-over-year change in Revenue: 28812000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 58876000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1877633 Filing: 000162619924000048 Input fundies:Revenue: 30064000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1878617 Filing: 000162619924000048
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 25.58 million

Prior period

−USD 57.76 million

2022-01-01 – 2022-12-31
Current period

−USD 32.18 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-32184000 − -57762000 = 25578000 USD

-57762000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-32184000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Year-over-year change in Net income: 25578000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -32184000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1480724 Filing: 000162619924000048 Input fundies:NetIncome: -57762000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1481507 Filing: 000162619924000048
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 35.26 million

Prior period

−USD 43.75 million

2022-01-01 – 2022-12-31
Current period

−USD 79.01 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-79012000 − -43754000 = -35258000 USD

-43754000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-79012000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Year-over-year change in Operating cash flow: -35258000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -79012000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1509730 Filing: 000162619924000048 Input fundies:OperatingCashFlow: -43754000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1510393 Filing: 000162619924000048
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+18.2%

Prior period

USD 412,000

2022-01-01 – 2022-12-31
Current period

USD 487,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

487000 − 412000 = 75000 USD

412000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
487000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Year-over-year change in Capital expenditure: 75000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 487000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1512578 Filing: 000162619924000048 Input fundies:CapitalExpenditure: 412000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1513142 Filing: 000162619924000048
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 58.88 million 100% of revenue
Operating costs Derived USD 103.13 million 175% of revenue
Operating income −USD 44.25 million −75% of revenue
Tax, interest and other Derived −USD 12.07 million −20% of revenue
Net income −USD 32.18 million −55% of revenue

Cash

Operating cash flow −USD 79.01 million −134% of revenue
Capital expenditure USD 487,000 0.8% of revenue
Free cash flow Derived −USD 79.5 million −135% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Operating loss: operating costs were 140% of revenue.
2017 Operating loss: operating costs were 965% of revenue.
2018 Operating loss: operating costs were 5,466% of revenue.
2019 Operating loss: operating costs were 2,604% of revenue.
2020 Operating loss: operating costs were 408% of revenue.
2021 Operating loss: operating costs were 313% of revenue.
2022 Operating loss: operating costs were 293% of revenue.
2023 Operating loss: operating costs were 175% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	0	14487000 Derived	-14487000	549000 Derived	-15036000	-14452000 Derived	Source 2014-01-01 – 2014-12-31: 0 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -14487000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -15036000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -14448000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 4000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	0	371000 Derived	-371000	-2000 Derived	-369000	4813000 Derived	Source 2015-01-01 – 2015-12-31: 0 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -371000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -369000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 4820000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 7000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	2950000	4138000 Derived	-1188000	44000 Derived	-1232000	-4579000 Derived	Source 2016-01-01 – 2016-12-31: 2950000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -1188000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -1232000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -3797000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 782000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	1731000	16705000 Derived	-14974000	-7191000 Derived	-7783000	-17158000 Derived	Source 2017-01-01 – 2017-12-31: 1731000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -14974000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -7783000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -16572000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 586000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	705000	38535000 Derived	-37830000	-1343000 Derived	-36487000	-28911000 Derived	Source 2018-01-01 – 2018-12-31: 705000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -37830000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -36487000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -28416000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 495000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1740000	45314000 Derived	-43574000	-1722000 Derived	-41852000	-36167000 Derived	Source 2019-01-01 – 2019-12-31: 1740000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -43574000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -41852000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -35346000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 821000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	9335000	38084000 Derived	-28749000	-809000 Derived	-27940000	29282000 Derived	Source 2020-01-01 – 2020-12-31: 9335000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -28749000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -27940000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 30084000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 802000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	23443000	73302000 Derived	-49859000	474000 Derived	-50333000	-15366000 Derived	Source 2021-01-01 – 2021-12-31: 23443000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -49859000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -50333000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -15248000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 118000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	30064000	88211000 Derived	-58147000	-385000 Derived	-57762000	-44166000 Derived	Source 2022-01-01 – 2022-12-31: 30064000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -58147000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -57762000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -43754000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 412000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	58876000	103126000 Derived	-44250000	-12066000 Derived	-32184000	-79499000 Derived	Source 2023-01-01 – 2023-12-31: 58876000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -44250000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -32184000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -79012000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 487000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 58.9M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	0	Revenue: 0 Open source
20152015-12-31	Revenue	0	Revenue: 0 Open source
20162016-12-31	Revenue	2950000	Revenue: 2950000 Open source
20172017-12-31	Revenue	1731000	Revenue: 1731000 Open source
20182018-12-31	Revenue	705000	Revenue: 705000 Open source
20192019-12-31	Revenue	1740000	Revenue: 1740000 Open source
20202020-12-31	Revenue	9335000	Revenue: 9335000 Open source
20212021-12-31	Revenue	23443000	Revenue: 23443000 Open source
20222022-12-31	Revenue	30064000	Revenue: 30064000 Open source
20232023-12-31	Revenue	58876000	Revenue: 58876000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

95.8% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20162016-12-31	Year over year	No prior comparable period	Revenue: 2950000 Open source Revenue: 0 Open source
20172017-12-31	Year over year	-41.3%	Revenue: 1731000 Open source Revenue: 2950000 Open source
20182018-12-31	Year over year	-59.3%	Revenue: 705000 Open source Revenue: 1731000 Open source
20192019-12-31	Year over year	146.8%	Revenue: 1740000 Open source Revenue: 705000 Open source
20202020-12-31	Year over year	436.5%	Revenue: 9335000 Open source Revenue: 1740000 Open source
20212021-12-31	Year over year	151.1%	Revenue: 23443000 Open source Revenue: 9335000 Open source
20222022-12-31	Year over year	28.2%	Revenue: 30064000 Open source Revenue: 23443000 Open source
20232023-12-31	Year over year	95.8%	Revenue: 58876000 Open source Revenue: 30064000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -75.2% 2023

Net margin -54.7% 2023

Free cash flow margin -135% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	Not reported	Operating Income: -14487000 Open source Revenue: 0 Open source
20152015-12-31	Operating margin	Not reported	Operating Income: -371000 Open source Revenue: 0 Open source
20162016-12-31	Operating margin	-40.3%	Operating Income: -1188000 Open source Revenue: 2950000 Open source
20172017-12-31	Operating margin	-865%	Operating Income: -14974000 Open source Revenue: 1731000 Open source
20182018-12-31	Operating margin	-5,366%	Operating Income: -37830000 Open source Revenue: 705000 Open source
20192019-12-31	Operating margin	-2,504.3%	Operating Income: -43574000 Open source Revenue: 1740000 Open source
20202020-12-31	Operating margin	-308%	Operating Income: -28749000 Open source Revenue: 9335000 Open source
20212021-12-31	Operating margin	-212.7%	Operating Income: -49859000 Open source Revenue: 23443000 Open source
20222022-12-31	Operating margin	-193.4%	Operating Income: -58147000 Open source Revenue: 30064000 Open source
20232023-12-31	Operating margin	-75.2%	Operating Income: -44250000 Open source Revenue: 58876000 Open source
20142014-12-31	Net margin	Not reported	Net Income: -15036000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	Not reported	Net Income: -369000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	-41.8%	Net Income: -1232000 Open source Revenue: 2950000 Open source
20172017-12-31	Net margin	-449.6%	Net Income: -7783000 Open source Revenue: 1731000 Open source
20182018-12-31	Net margin	-5,175.5%	Net Income: -36487000 Open source Revenue: 705000 Open source
20192019-12-31	Net margin	-2,405.3%	Net Income: -41852000 Open source Revenue: 1740000 Open source
20202020-12-31	Net margin	-299.3%	Net Income: -27940000 Open source Revenue: 9335000 Open source
20212021-12-31	Net margin	-214.7%	Net Income: -50333000 Open source Revenue: 23443000 Open source
20222022-12-31	Net margin	-192.1%	Net Income: -57762000 Open source Revenue: 30064000 Open source
20232023-12-31	Net margin	-54.7%	Net Income: -32184000 Open source Revenue: 58876000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -14448000 Open source Capital Expenditure: 4000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: 4820000 Open source Capital Expenditure: 7000 Open source
20162016-12-31	Free cash flow margin	-155.2%	Revenue: 2950000 Open source Operating Cash Flow: -3797000 Open source Capital Expenditure: 782000 Open source
20172017-12-31	Free cash flow margin	-991.2%	Revenue: 1731000 Open source Operating Cash Flow: -16572000 Open source Capital Expenditure: 586000 Open source
20182018-12-31	Free cash flow margin	-4,100.9%	Revenue: 705000 Open source Operating Cash Flow: -28416000 Open source Capital Expenditure: 495000 Open source
20192019-12-31	Free cash flow margin	-2,078.6%	Revenue: 1740000 Open source Operating Cash Flow: -35346000 Open source Capital Expenditure: 821000 Open source
20202020-12-31	Free cash flow margin	313.7%	Revenue: 9335000 Open source Operating Cash Flow: 30084000 Open source Capital Expenditure: 802000 Open source
20212021-12-31	Free cash flow margin	-65.5%	Revenue: 23443000 Open source Operating Cash Flow: -15248000 Open source Capital Expenditure: 118000 Open source
20222022-12-31	Free cash flow margin	-146.9%	Revenue: 30064000 Open source Operating Cash Flow: -43754000 Open source Capital Expenditure: 412000 Open source
20232023-12-31	Free cash flow margin	-135%	Revenue: 58876000 Open source Operating Cash Flow: -79012000 Open source Capital Expenditure: 487000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -79M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-14448000	Operating Cash Flow: -14448000 Open source
20152015-12-31	Operating cash flow	4820000	Operating Cash Flow: 4820000 Open source
20162016-12-31	Operating cash flow	-3797000	Operating Cash Flow: -3797000 Open source
20172017-12-31	Operating cash flow	-16572000	Operating Cash Flow: -16572000 Open source
20182018-12-31	Operating cash flow	-28416000	Operating Cash Flow: -28416000 Open source
20192019-12-31	Operating cash flow	-35346000	Operating Cash Flow: -35346000 Open source
20202020-12-31	Operating cash flow	30084000	Operating Cash Flow: 30084000 Open source
20212021-12-31	Operating cash flow	-15248000	Operating Cash Flow: -15248000 Open source
20222022-12-31	Operating cash flow	-43754000	Operating Cash Flow: -43754000 Open source
20232023-12-31	Operating cash flow	-79012000	Operating Cash Flow: -79012000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -79.5M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-14452000	Operating Cash Flow: -14448000 Open source Capital Expenditure: 4000 Open source
20152015-12-31	Free cash flow	4813000	Operating Cash Flow: 4820000 Open source Capital Expenditure: 7000 Open source
20162016-12-31	Free cash flow	-4579000	Operating Cash Flow: -3797000 Open source Capital Expenditure: 782000 Open source
20172017-12-31	Free cash flow	-17158000	Operating Cash Flow: -16572000 Open source Capital Expenditure: 586000 Open source
20182018-12-31	Free cash flow	-28911000	Operating Cash Flow: -28416000 Open source Capital Expenditure: 495000 Open source
20192019-12-31	Free cash flow	-36167000	Operating Cash Flow: -35346000 Open source Capital Expenditure: 821000 Open source
20202020-12-31	Free cash flow	29282000	Operating Cash Flow: 30084000 Open source Capital Expenditure: 802000 Open source
20212021-12-31	Free cash flow	-15366000	Operating Cash Flow: -15248000 Open source Capital Expenditure: 118000 Open source
20222022-12-31	Free cash flow	-44166000	Operating Cash Flow: -43754000 Open source Capital Expenditure: 412000 Open source
20232023-12-31	Free cash flow	-79499000	Operating Cash Flow: -79012000 Open source Capital Expenditure: 487000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

13.7% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Liabilities / assets	Not reported	No source recorded
2015-12-31	Liabilities / assets	Not reported	Total Assets: 87909000 Open source
20162016-12-31	Liabilities / assets	20%	Total Liabilities: 2517000 Open source Total Assets: 12595000 Open source
20172017-12-31	Liabilities / assets	7.4%	Total Liabilities: 6305000 Open source Total Assets: 85222000 Open source
20182018-12-31	Liabilities / assets	18.7%	Total Liabilities: 10282000 Open source Total Assets: 54873000 Open source
20192019-12-31	Liabilities / assets	45.5%	Total Liabilities: 24619000 Open source Total Assets: 54093000 Open source
20202020-12-31	Liabilities / assets	56.9%	Total Liabilities: 81932000 Open source Total Assets: 144090000 Open source
20212021-12-31	Liabilities / assets	52.8%	Total Liabilities: 134997000 Open source Total Assets: 255900000 Open source
20222022-12-31	Liabilities / assets	37.4%	Total Liabilities: 107266000 Open source Total Assets: 286686000 Open source
20232023-12-31	Liabilities / assets	13.7%	Total Liabilities: 51911000 Open source Total Assets: 379852000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.86× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
20152015-12-31	Current assets / current liabilities	19.84×	Current Assets: 87686000 Open source Current Liabilities: 4419000 Open source
20162016-12-31	Current assets / current liabilities	4.93×	Current Assets: 11855000 Open source Current Liabilities: 2404000 Open source
20172017-12-31	Current assets / current liabilities	43.56×	Current Assets: 82548000 Open source Current Liabilities: 1895000 Open source
20182018-12-31	Current assets / current liabilities	6.59×	Current Assets: 53545000 Open source Current Liabilities: 8127000 Open source
20192019-12-31	Current assets / current liabilities	4.87×	Current Assets: 42302000 Open source Current Liabilities: 8681000 Open source
20202020-12-31	Current assets / current liabilities	2.6×	Current Assets: 107101000 Open source Current Liabilities: 41167000 Open source
20212021-12-31	Current assets / current liabilities	2.75×	Current Assets: 192013000 Open source Current Liabilities: 69778000 Open source
20222022-12-31	Current assets / current liabilities	4.16×	Current Assets: 240993000 Open source Current Liabilities: 57996000 Open source
20232023-12-31	Current assets / current liabilities	7.86×	Current Assets: 330034000 Open source Current Liabilities: 41980000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 15.04 million Exact value Exact value: -15036000 USD 2014-01-01 – 2014-12-31: -15036000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2014-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -15036000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15036000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000119312517176826/nvls-20170331.xml#246887 Filing: 000119312517176826 The citation records this snapshot. The page link may show a newer release later.	−USD 14.45 million Exact value Exact value: -14448000 USD 2014-01-01 – 2014-12-31: -14448000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2014-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -14448000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14448000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000119312517176826/nvls-20170331.xml#243763 Filing: 000119312517176826 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2014-01-01 – 2014-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2014-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000119312517176826/nvls-20170331.xml#246151 Filing: 000119312517176826 The citation records this snapshot. The page link may show a newer release later.	−USD 14.45 million Calculation and evidence -14448000 − 4000 USD Exact free cash flow: -14452000 USD 2014-01-01 – 2014-12-31: -14448000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2014-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -14452000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14448000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000119312517176826/nvls-20170331.xml#243763 Filing: 000119312517176826 Input fundies:CapitalExpenditure: 4000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000119312517176826/nvls-20170331.xml#246151 Filing: 000119312517176826 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 369,000 Exact value Exact value: -369000 USD 2015-01-01 – 2015-12-31: -369000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2015-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -369000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -369000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-20171231.xml#109167 Filing: 000156459018006916 The citation records this snapshot. The page link may show a newer release later.	USD 4.82 million Exact value Exact value: 4820000 USD 2015-01-01 – 2015-12-31: 4820000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2015-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: 4820000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4820000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-20171231.xml#136695 Filing: 000156459018006916 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2015-01-01 – 2015-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2015-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-20171231.xml#137323 Filing: 000156459018006916 The citation records this snapshot. The page link may show a newer release later.	USD 4.81 million Calculation and evidence 4820000 − 7000 USD Exact free cash flow: 4813000 USD 2015-01-01 – 2015-12-31: 4820000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2015-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: 4813000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4820000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-20171231.xml#136695 Filing: 000156459018006916 Input fundies:CapitalExpenditure: 7000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-20171231.xml#137323 Filing: 000156459018006916 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 1.23 million Exact value Exact value: -1232000 USD 2016-01-01 – 2016-12-31: -1232000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2016-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -1232000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1232000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/alpn-20181231.xml#238069 Filing: 000162619919000010 The citation records this snapshot. The page link may show a newer release later.	−USD 3.8 million Exact value Exact value: -3797000 USD 2016-01-01 – 2016-12-31: -3797000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2016-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -3797000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3797000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/alpn-20181231.xml#237434 Filing: 000162619919000010 The citation records this snapshot. The page link may show a newer release later.	USD 782,000 Exact value Exact value: 782000 USD 2016-01-01 – 2016-12-31: 782000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2016-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 782000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 782000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/alpn-20181231.xml#249201 Filing: 000162619919000010 The citation records this snapshot. The page link may show a newer release later.	−USD 4.58 million Calculation and evidence -3797000 − 782000 USD Exact free cash flow: -4579000 USD 2016-01-01 – 2016-12-31: -3797000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 782000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2016-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -4579000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3797000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/alpn-20181231.xml#237434 Filing: 000162619919000010 Input fundies:CapitalExpenditure: 782000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/alpn-20181231.xml#249201 Filing: 000162619919000010 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 7.78 million Exact value Exact value: -7783000 USD 2017-01-01 – 2017-12-31: -7783000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2017-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -7783000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7783000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/a10k2019.htm#1836550 Filing: 000162619920000009 The citation records this snapshot. The page link may show a newer release later.	−USD 16.57 million Exact value Exact value: -16572000 USD 2017-01-01 – 2017-12-31: -16572000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2017-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -16572000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16572000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/a10k2019.htm#1877619 Filing: 000162619920000009 The citation records this snapshot. The page link may show a newer release later.	USD 586,000 Exact value Exact value: 586000 USD 2017-01-01 – 2017-12-31: 586000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2017-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 586000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 586000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/a10k2019.htm#1882076 Filing: 000162619920000009 The citation records this snapshot. The page link may show a newer release later.	−USD 17.16 million Calculation and evidence -16572000 − 586000 USD Exact free cash flow: -17158000 USD 2017-01-01 – 2017-12-31: -16572000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 586000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2017-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -17158000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16572000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/a10k2019.htm#1877619 Filing: 000162619920000009 Input fundies:CapitalExpenditure: 586000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/a10k2019.htm#1882076 Filing: 000162619920000009 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 36.49 million Exact value Exact value: -36487000 USD 2018-01-01 – 2018-12-31: -36487000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2018-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -36487000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36487000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-20201231.htm#1785397 Filing: 000162619921000038 The citation records this snapshot. The page link may show a newer release later.	−USD 28.42 million Exact value Exact value: -28416000 USD 2018-01-01 – 2018-12-31: -28416000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2018-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -28416000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28416000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-20201231.htm#1827240 Filing: 000162619921000038 The citation records this snapshot. The page link may show a newer release later.	USD 495,000 Exact value Exact value: 495000 USD 2018-01-01 – 2018-12-31: 495000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2018-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 495000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 495000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-20201231.htm#1831069 Filing: 000162619921000038 The citation records this snapshot. The page link may show a newer release later.	−USD 28.91 million Calculation and evidence -28416000 − 495000 USD Exact free cash flow: -28911000 USD 2018-01-01 – 2018-12-31: -28416000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 495000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2018-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -28911000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28416000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-20201231.htm#1827240 Filing: 000162619921000038 Input fundies:CapitalExpenditure: 495000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-20201231.htm#1831069 Filing: 000162619921000038 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 41.85 million Exact value Exact value: -41852000 USD 2019-01-01 – 2019-12-31: -41852000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2019-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -41852000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41852000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231.htm#1639789 Filing: 000162619922000032 The citation records this snapshot. The page link may show a newer release later.	−USD 35.35 million Exact value Exact value: -35346000 USD 2019-01-01 – 2019-12-31: -35346000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2019-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -35346000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35346000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231.htm#1678665 Filing: 000162619922000032 The citation records this snapshot. The page link may show a newer release later.	USD 821,000 Exact value Exact value: 821000 USD 2019-01-01 – 2019-12-31: 821000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2019-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 821000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 821000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231.htm#1682511 Filing: 000162619922000032 The citation records this snapshot. The page link may show a newer release later.	−USD 36.17 million Calculation and evidence -35346000 − 821000 USD Exact free cash flow: -36167000 USD 2019-01-01 – 2019-12-31: -35346000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 821000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2019-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -36167000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35346000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231.htm#1678665 Filing: 000162619922000032 Input fundies:CapitalExpenditure: 821000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231.htm#1682511 Filing: 000162619922000032 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 27.94 million Exact value Exact value: -27940000 USD 2020-01-01 – 2020-12-31: -27940000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2020-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -27940000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27940000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619923000037/alpn-20221231.htm#1425441 Filing: 000162619923000037 The citation records this snapshot. The page link may show a newer release later.	USD 30.08 million Exact value Exact value: 30084000 USD 2020-01-01 – 2020-12-31: 30084000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2020-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: 30084000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 30084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619923000037/alpn-20221231.htm#1454466 Filing: 000162619923000037 The citation records this snapshot. The page link may show a newer release later.	USD 802,000 Exact value Exact value: 802000 USD 2020-01-01 – 2020-12-31: 802000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2020-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 802000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619923000037/alpn-20221231.htm#1457297 Filing: 000162619923000037 The citation records this snapshot. The page link may show a newer release later.	USD 29.28 million Calculation and evidence 30084000 − 802000 USD Exact free cash flow: 29282000 USD 2020-01-01 – 2020-12-31: 30084000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 802000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2020-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: 29282000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 30084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619923000037/alpn-20221231.htm#1454466 Filing: 000162619923000037 Input fundies:CapitalExpenditure: 802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619923000037/alpn-20221231.htm#1457297 Filing: 000162619923000037 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 50.33 million Exact value Exact value: -50333000 USD 2021-01-01 – 2021-12-31: -50333000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2021-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -50333000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50333000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1482291 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 15.25 million Exact value Exact value: -15248000 USD 2021-01-01 – 2021-12-31: -15248000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2021-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -15248000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15248000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1511057 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	USD 118,000 Exact value Exact value: 118000 USD 2021-01-01 – 2021-12-31: 118000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2021-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 118000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 118000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1513707 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 15.37 million Calculation and evidence -15248000 − 118000 USD Exact free cash flow: -15366000 USD 2021-01-01 – 2021-12-31: -15248000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 118000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2021-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -15366000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15248000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1511057 Filing: 000162619924000048 Input fundies:CapitalExpenditure: 118000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1513707 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 57.76 million Exact value Exact value: -57762000 USD 2022-01-01 – 2022-12-31: -57762000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2022-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -57762000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57762000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1481507 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 43.75 million Exact value Exact value: -43754000 USD 2022-01-01 – 2022-12-31: -43754000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2022-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -43754000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43754000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1510393 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	USD 412,000 Exact value Exact value: 412000 USD 2022-01-01 – 2022-12-31: 412000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2022-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 412000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 412000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1513142 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 44.17 million Calculation and evidence -43754000 − 412000 USD Exact free cash flow: -44166000 USD 2022-01-01 – 2022-12-31: -43754000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 412000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2022-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -44166000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43754000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1510393 Filing: 000162619924000048 Input fundies:CapitalExpenditure: 412000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1513142 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 32.18 million Exact value Exact value: -32184000 USD 2023-01-01 – 2023-12-31: -32184000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Net Income: -32184000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32184000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1480724 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 79.01 million Exact value Exact value: -79012000 USD 2023-01-01 – 2023-12-31: -79012000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Operating Cash Flow: -79012000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -79012000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1509730 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	USD 487,000 Exact value Exact value: 487000 USD 2023-01-01 – 2023-12-31: 487000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Capital Expenditure: 487000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 487000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1512578 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.	−USD 79.5 million Calculation and evidence -79012000 − 487000 USD Exact free cash flow: -79499000 USD 2023-01-01 – 2023-12-31: -79012000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 487000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALPINE IMMUNE SCIENCES, INC. · 2023-12-31 ALPINE IMMUNE SCIENCES, INC. (edgar:1626199) Free cash flow: -79499000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:23:53Z Snapshot: 5b62a0047d9764da944be07503c619443b7da366319fae85e9eaf3cad5654973 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1626199?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -79012000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1509730 Filing: 000162619924000048 Input fundies:CapitalExpenditure: 487000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm#1512578 Filing: 000162619924000048 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

78 filings · 2,653 latest values · 2,651 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001626199, 1626199, ALPN, NVLS, edgar:1626199

Also known as ALPINE IMMUNE SCIENCES, INC., Alpine Immune Sciences, Inc., N30 Pharmaceuticals, Inc., Nivalis Therapeutics, Inc.

ALPINE IMMUNE SCIENCES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation